Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant docetaxel + carboplatin with or without iniparib in early-stage triple-negative breast cancer
2010-023400-28Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of iniparib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sanofi. Primary endpoint: Pathological complete response in breast and axillary lymph nodes. Started Dec 2010; status: completed.
02
Drugs
iniparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2010-023400-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023400-28.